Patent US4874774A successfully refreshed from Google Patents.
US4874774A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Nifedipine compositions and the production thereof
Assignee: Nippon Shinyaku Co Ltd
•
Filing: 1986-08-12
•
Granted: 1989-10-17
•
Expires: 2006-08-12
Abstract
Abstract Nifedipine is formulated into a reactally administrable composition for administration to humans and animals to effect coronary dilation and for hypotensive effect.
Inventors
- 👤 Koichi Ushimaru
- 👤 Tomoaki Hamakawa
- 👤 Tomio Koga
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 01:59
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/02; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/44; Y; Y10; Y10S; Y10S424/00; Y10S424/15
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
67 words
A pharmaceutical composition in rectal administration form which comprises a coronary vasodilating effective amount or a hypotensively effective amount of 1,4-dihydro-2,6-dimethyl-4-(2'-nitrophenyl)3,5-dicarbomethoxy-pyridine in combination with a pharmaceutically accepable carrier suitable for formulating rectally administrable compositions which comprises a mixture of 5 to 50 parts by weight of a polyethylene glycol and 50 to 95 parts by weight of a fatty acid glyceride of 12 to 18 carbon atoms.
Claim 2
Dependent Claim
67 words
A pharmaceutical composition in rectal administration form which comprises a coronary vasodilating effective amount or a hypotensively effective amount of 1,4-dihydro-2,6-dimethyl-4-(2'-nitrophenyl)3,5-dicarbomethoxy-pyridine in combination with a pharmaceutically accepable carrier suitable for formulating rectally administrable compositions which comprises a mixture of 5 to 50 parts by weight of a polyethylene glycol and 50 to 95 parts by weight of a fatty acid glyceride of 12 to 18 carbon atoms.
Claim 3
Dependent Claim
19 words
A composition according to claim 1 wherein the polyethylene glycol has a molecular weight of from 200 to 20,000.
Claim 4
Dependent Claim
18 words
A composition according to claim 1 which contains from about 0.1 to about 5% by weight of 1,4-dihydro-2,6-dimethyl-4-(2'-nitrophenyl)-3,5-dicarbomethoxypyridine.
Claim 5
Dependent Claim
18 words
A composition according to claim 1 which contains from about 0.25 to about 2% by weight of 1,4-dihydro-2,6-dimethyl-4-(2'-nitrophenyl)-3,5-dicarbomethoxypyridine.
Claim 6
Independent Claim
80 words
A method of effecting coronary vasodilation in humans and animals which comprises rectally administering to a human or animal in need thereof a pharmaceutical composition which comprises a coronary vasodilating effective amount of 1,4-dihydro-2,6-dimethyl-4-(2'-nitrophenyl)3,5-dicarbo-methoxypyridine in combination with a pharmaceutically acceptable carrier suitable for formulating rectally administrable composition which comprises a mixture of 5 to 50 parts by weight of a polyethylene glycol and 50 to 95 parts by weight of a fatty acid glyceride of 12 to 18 carbon atoms.
Claim 7
Independent Claim
80 words
A method of effecting coronary vasodilation in humans and animals which comprises rectally administering to a human or animal in need thereof a pharmaceutical composition which comprises a coronary vasodilating effective amount of 1,4-dihydro-2,6-dimethyl-4-(2'-nitrophenyl)3,5-dicarbo-methoxypyridine in combination with a pharmaceutically acceptable carrier suitable for formulating rectally administrable composition which comprises a mixture of 5 to 50 parts by weight of a polyethylene glycol and 50 to 95 parts by weight of a fatty acid glyceride of 12 to 18 carbon atoms.
Claim 8
Dependent Claim
19 words
A method according to claim 5 wherein the polyethylene glycol has a molecular weight of from 200 to 20,000.
Claim 9
Dependent Claim
25 words
A method according to claim 5 which comprises rectally administering suppositories wherein each suppository contains from about 0.1 to about 5% by weight of 1,4-dihydro-2,6-dimethyl-4-(2'-nitrophenyl)-3,5-dicarbomethoxypyridine.
Claim 10
Dependent Claim
25 words
A method according to claim 5 which comprises rectally administering suppositories wherein each suppository contains from about 0.25 to about 2% by weight of 1,4-dihydro-2,6-dimethyl-4-(2'-nitrophenyl)-3,5-dicarbomethoxypyridine.
Claim 11
Independent Claim
78 words
A method of treating hypertension in humans and animals which comprises rectally adminstering to a human or animal in need thereof a pharmaceutical composition which comprises a hypotensively effective amount of 1,4-dihydro-2,6-di-methyl-4-(2'-nitrophenyl)3,5-dicarbo-methoxy-pyridine in combination with a pharmaceutically acceptable carrier suitable for formulating rectally administrable composition which comprises a mixture of 5 to 50 parts by weight of a polyethylene glycol and 50 to 95 parts by weight of a fatty acid glyceride of 12 to 18 carbon atoms.
Claim 12
Independent Claim
78 words
A method of treating hypertension in humans and animals which comprises rectally adminstering to a human or animal in need thereof a pharmaceutical composition which comprises a hypotensively effective amount of 1,4-dihydro-2,6-di-methyl-4-(2'-nitrophenyl)3,5-dicarbo-methoxy-pyridine in combination with a pharmaceutically acceptable carrier suitable for formulating rectally administrable composition which comprises a mixture of 5 to 50 parts by weight of a polyethylene glycol and 50 to 95 parts by weight of a fatty acid glyceride of 12 to 18 carbon atoms.
Claim 13
Dependent Claim
19 words
A method according to claim 9 wherein the polyethylene glycol has a molecular weight of from 200 to 20,000.
Claim 14
Dependent Claim
25 words
A method according to claim 9 which comprises rectally administering suppositories wherein each suppository contains from about 0.1 to about 5% by weight of 1,4-dihydro-2,6-dimethyl-4-(2'-nitrophenyl)-3,5-dicarbomethoxypryidine.
Claim 15
Dependent Claim
25 words
A method according to claim 9 which comprises rectally administering suppositories wherein each suppository contains from about 0.25 to about 2% by weight of 1,4-dihydro-2,6-dimethyl-4-(2'-nitrophenyl)-3,5-dicarbomethoxypyridine.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-10-16 | 1993-04-17 | 1993-10-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-10-16 | 1997-04-17 | 1997-10-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-10-16 | 2001-04-17 | 2001-10-17 | $7700.00 | Window Closed / Lapsed |